GOVX: GeoVax Conference Participation

By John Vandermosten, CFA

OTC:GOVX

GeoVax Labs, Inc. (OTC:GOVX) participated in several conferences in the last weeks of October, including the HIVR4P conference in Madrid, Spain, the ISV in Atlanta, Georgia and the World Vaccine Congress in Lisbon, Portugal. Below, we provide a summary of the poster presentation and the other scientific conferences where the company has presented.

Paul Goepfert, M.D. of the University of Alabama presented at the HIVR4P conference announcing positive results from the HVTN 114 trial which tested a late protein boost of AIDSVAX B/E in participants from a phase 2a trial of GeoVax’s GOVX-B11 preventive HIV vaccine candidate. The trial was conducted by the HIV Vaccine Trials Network (HVTN) with financial support from the National Institute of Health (NIH). In conjunction with the presentation, a poster was submitted.

The GOVX-B11 has two components that work in tandem to prime a protective immune response and boost it. The HVTN 114 trial enrolled 27 patients and tested the effectiveness of a boost approximately seven years after the initial vaccination to elicit a response from antibodies. Results demonstrated a broadened antibody response from both the neutralizing antibody and the binding antibody. Below, we include the figure from the poster illustrating the antibody impact from AIDSVAX B/E both with and without GeoVax’s MVA/HIV62B vaccine. The figure shows that individuals receiving the AIDSVAX B/E boost demonstrated a better response of neutralizing antibodies against HIV strains MN.3 as compared to the GeoVax vaccine by itself.


View Exhibit I – Neutralizing Antibody Response1

The poster also examined the binding antibody response for gp120, gp140 and gp41, which are HIV envelope exposed glycoproteins. The AIDSVAX B/E that contained a boost brought about a greater response in gp120 and gp140 specific IgG binding antibody responses, while gp41 was similar in the included observations.


View Exhibit II – IgG Binding Antibody Responses2

The data presented in the poster demonstrate an improved antibody response for individuals who received a boost of AIDSVAX B/E after an initial vaccination with GeoVax’s DNA/MVA vaccine regimen. The scientific team concluded that a broader antibody response is a beneficial feature for a vaccine designed to prevent HIV infection.

The second October event is the 2018 Annual Congress International Society for Vaccines (ISV) meeting. The conference hosted a talk on Sunday, October 28th where GeoVax Director of Vector Development, Dr. Arban Domi presented “Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP Vector.” The presentation highlighted GeoVax’s modified vaccinia Ankara (MVA) platform for infectious diseases and oncology. GeoVax’s MVA-virus like particle (VLP) provides several advantages to traditional vaccines, including limited pre-existing immunity to the target vector, ability to use the vector for multiple targets and no need for adjuvants among other benefits.

GeoVax’s third October presentation was held in Lisbon, Portugal on October 29 where Dr. Farshad Guirakhoo will present “MVA-VLP As A Plug And Play Platform For Development Of Safe And Effective Single Dose Vaccines For Emerging Infectious Diseases, Preclinical Data For Zika, Ebola And Lassa As Examples.” The presentation was part of the World Vaccine Congress held during the last days of October. Dr. Guirakhoo’s presentation will discuss GeoVax’s single dose preventative vaccines for Zika, Ebola and Lassa.

GeoVax will also be participating in the World Vaccine and Immunotherapy conference in San Diego, California in late November 2018.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.


__________________________
1 T1: MVA/HIV62B post MMM / T2: MVA/HIV62B + AIDSVAX B/E post MMM / T3: MVA/HIV62B post DDMM / T4: MVA/HIV62B + AIDSVAX B/E post DDMM / T5: AIDSVAX B/E post DDMM
2 T1: MVA/HIV62B post MMM / T2: MVA/HIV62B + AIDSVAX B/E post MMM / T3: MVA/HIV62B post DDMM / T4: MVA/HIV62B + AIDSVAX B/E post DDMM / T5: AIDSVAX B/E post DDMM

COMMENTS

WORDPRESS: 0
DISQUS: 0